910378-55-1

Basic information

• Product Name: Butanoic acid, 2-[3-[3-(4-Methoxybenzoyl)-2-Methyl-6-(trifluoroMethoxy)-1H-indol-1-yl]phenoxy]-, hydrate (1:2), (2R)-
• Synonyms: Butanoic acid, 2-[3-[3-(4-Methoxybenzoyl)-2-Methyl-6-(trifluoroMethoxy)-1H-indol-1-yl]phenoxy]-, hydrate (1:2), (2R)-;IYPIJSKHFOMNRC-PPLJNSMQSA-N
• CAS NO: 910378-55-1
• Molecular Formula: C28H28F3NO8
• Molecular Weight: 563.5190296
• Mol File: 910378-55-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Butanoic acid, 2-[3-[3-(4-Methoxybenzoyl)-2-Methyl-6-(trifluoroMethoxy)-1H-indol-1-yl]phenoxy]-, hydrate (1:2), (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-[3-[3-(4-Methoxybenzoyl)-2-Methyl-6-(trifluoroMethoxy)-1H-indol-1-yl]phenoxy]-, hydrate (1:2), (2R)-(910378-55-1)
• EPA Substance Registry System: Butanoic acid, 2-[3-[3-(4-Methoxybenzoyl)-2-Methyl-6-(trifluoroMethoxy)-1H-indol-1-yl]phenoxy]-, hydrate (1:2), (2R)-(910378-55-1)

Safety Data

• Hazardous Substances Data: 910378-55-1(Hazardous Substances Data)

Relevant articles and documents

NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS

Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.